Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabKimio Yonesaka, Pasi A. Jänne, Dalia Ercan et al.|Science Translational Medicine|2011Cited by 670
B7-H3 Negatively Modulates CTL-Mediated Cancer ImmunityKimio Yonesaka, Kazuhiko Nakagawa, Koji Haratani et al.|Clinical Cancer Research|2018Cited by 169
Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung CancerJunko Tanizaki, Kazuhiko Nakagawa, Isamu Okamoto et al.|Clinical Cancer Research|2012Cited by 156